Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Guggenheim lowered its price target on Amgen to $340 from $351 while keeping a Neutral rating, a modest 3.1% reduction. The note signals slightly more cautious expectations for the stock, but the unchanged rating limits the overall bearishness. This is routine analyst commentary and should have limited market-wide impact.

Analysis

Guggenheim lowered its price target on Amgen to $340 from $351 while keeping a Neutral rating, a modest 3.1% reduction. The note signals slightly more cautious expectations for the stock, but the unchanged rating limits the overall bearishness. This is routine analyst commentary and should have limited market-wide impact.